As miR-1305 has been described to be playing a tumor-suppressing role by suppressing the expressions of IGF1, FGF2, and MDM2, the low intracellular level of miR-1305 would the poor prognosis among multiple myeloma patients and it was hypothesized that the exosomal release of miR-1305 was linked to the low survival among the multiple myeloma patients [130]. This evidence concerns the gene MDM2 and plasma cell myeloma.